{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:40:11Z","timestamp":1793742011673,"version":"4.6.1"},"reference-count":173,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017006","name":"Abramson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K99CA212302-01A1"],"award-info":[{"award-number":["1K99CA212302-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010347","name":"Fabrikant Einar Willumsens Mindelegat","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006458","name":"Children's Hospital of Philadelphia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007929","name":"Institute for Translational Medicine and Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007929","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jcyt.2019.12.004","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T20:32:23Z","timestamp":1580502743000},"page":"57-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"title":["The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3360-7725","authenticated-orcid":false,"given":"Peter","family":"Braendstrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0001","first-page":"467","article-title":"Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2019.12.004_bib0002","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"Journal for immunotherapy of cancer"},{"issue":"20 Pt 1","key":"10.1016\/j.jcyt.2019.12.004_bib0004","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clinical cancer research"},{"issue":"13","key":"10.1016\/j.jcyt.2019.12.004_bib0005","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"Journal of clinical oncology"},{"issue":"11","key":"10.1016\/j.jcyt.2019.12.004_bib0006","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nature medicine"},{"issue":"4","key":"10.1016\/j.jcyt.2019.12.004_bib0007","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Molecular therapy"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0008","unstructured":"Roberts MR, Chimeric receptor molecules for delivery of co-stimulatory signals, 1995.http:\/\/patft.uspto.gov\/netacgi\/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=55&f=G&l=50&d=PTXT&s1=5,712,149&p=2&OS=5,712,149&RS=5,712,149. (Accessed July 24, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0009","unstructured":"Bebbington CR, Lawson AD, Weir N, Finney HM, Cell Activation Process And Reagents Therefor, 1996. https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO1997023613&tab=PCTBIBLIO. (Accessed July 24, 2019)."},{"issue":"6","key":"10.1016\/j.jcyt.2019.12.004_bib0010","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2019.12.004_bib0011","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"The Journal of experimental medicine"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0012","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain","volume":"172","author":"Finney","year":"2004","journal-title":"Journal of immunology (Baltimore, Md.: 1950)"},{"issue":"4","key":"10.1016\/j.jcyt.2019.12.004_bib0013","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"18 Pt 1","key":"10.1016\/j.jcyt.2019.12.004_bib0014","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clinical cancer research"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0015","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Molecular therapy"},{"issue":"20","key":"10.1016\/j.jcyt.2019.12.004_bib0016","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0017","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"18","key":"10.1016\/j.jcyt.2019.12.004_bib0018","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jcyt.2019.12.004_bib0019","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"177","key":"10.1016\/j.jcyt.2019.12.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Science translational medicine"},{"issue":"16","key":"10.1016\/j.jcyt.2019.12.004_bib0021","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0022","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"The New England journal of medicine"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0024","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0025","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"The Journal of clinical investigation"},{"issue":"9967","key":"10.1016\/j.jcyt.2019.12.004_bib0026","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0027","unstructured":"US Food and Drug Administration, FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome, 2017. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm574154.htm. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0028","unstructured":"US Food and Drug Administration, FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma, 2018. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm606540.htm. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0029","unstructured":"European Medicines Agency, Kymriah, 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kymriah. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0030","unstructured":"Health Canada, Regulatory Decision Summary for Kymriah (Control no. 213547), 2018. https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?linkID=RDS00423. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0031","unstructured":"Health Canada, Regulatory Decision Summary for Kymriah (Control no. 213698), 2018. https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?linkID=RDS00422. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0032","unstructured":"Swissmedic, Kymriah TM, Zellsuspension zur Infusion (Tisagenlecleucelum), 2018. https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/authorised-medicinal-products-with-new-active-substances\/kymriahtm_zellsuspensionzurinfusiontisagenlecleucelum.html. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0033","unstructured":"Therapeutic Goods Administration, Inclusions of new biologicals, 2018. https:\/\/www.tga.gov.au\/inclusions-new-biologicals. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0034","unstructured":"Oxford Biomedica, Oxford Biomedica notes the Japanese approval of Kymriah\u00ae (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia, 2019. https:\/\/www.oxfordbiomedica.co.uk\/news-media\/press-release\/oxford-biomedica-notes-japanese-approval-kymriah%C2%AE-tisagenlecleucel-first. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0035","unstructured":"European Medicines Agency, Yescarta, 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yescarta. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0036","unstructured":"Health Canada, Regulatory Decision Summary\u2014Yescarta\u2014Health Canada, 2019. https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00486. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0037","unstructured":"Swissmedic, Yescarta\u00ae, 0,4 \u2013 2 x 108 Zellen Infusionsdispersion (axicabtagene ciloleucel), 2019. https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/authorised-medicinal-products-with-new-active-substances\/yescarta_zellen_infusionsdispersion_axicabtagene_ciloleucel.html. (Accessed September 28, 2019)."},{"issue":"3","key":"10.1016\/j.jcyt.2019.12.004_bib0038","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/ehm.10.21","article-title":"Allogeneic hematopoietic cell transplantation: the state of the art","volume":"3","author":"Gyurkocza","year":"2010","journal-title":"Expert review of hematology"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0039","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.V78.8.2120.2120","article-title":"T-cell depletion of HLA-identical transplants in leukemia","volume":"78","author":"Marmont","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymthe.2005.09.011","article-title":"Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders","volume":"13","author":"Baron","year":"2006","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.jcyt.2019.12.004_bib0041","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/bmt.2015.288","article-title":"New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT","volume":"51","author":"Chang","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0042","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ng1092-93","article-title":"A brief history of gene therapy","volume":"2","author":"Friedmann","year":"1992","journal-title":"Nature genetics"},{"issue":"3","key":"10.1016\/j.jcyt.2019.12.004_bib0043","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"10.1016\/j.jcyt.2019.12.004_bib0044","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0045","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0046","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0047","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0092-8674(91)90327-U","article-title":"Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides","volume":"64","author":"Romeo","year":"1991","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.jcyt.2019.12.004_bib0048","doi-asserted-by":"crossref","first-page":"8905","DOI":"10.1073\/pnas.88.20.8905","article-title":"T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins","volume":"88","author":"Letourneur","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"25","key":"10.1016\/j.jcyt.2019.12.004_bib0049","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"The New England journal of medicine"},{"issue":"9","key":"10.1016\/j.jcyt.2019.12.004_bib0050","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene transfer into humans\u2014immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction","volume":"323","author":"Rosenberg","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0051","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.178.1.361","article-title":"Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain","volume":"178","author":"Hwu","year":"1993","journal-title":"The Journal of experimental medicine"},{"issue":"15","key":"10.1016\/j.jcyt.2019.12.004_bib0052","first-page":"3369","article-title":"In vivo antitumor activity of T cells redirected with chimeric antibody\/T-cell receptor genes","volume":"55","author":"Hwu","year":"1995","journal-title":"Cancer research"},{"issue":"5594","key":"10.1016\/j.jcyt.2019.12.004_bib0053","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science (New York, N.Y.)"},{"issue":"6","key":"10.1016\/j.jcyt.2019.12.004_bib0054","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1182\/blood-2003-01-0095","article-title":"Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed\/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation","volume":"102","author":"Laport","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0056","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clinical cancer research"},{"issue":"10","key":"10.1016\/j.jcyt.2019.12.004_bib0057","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.91.10.4318","article-title":"Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells","volume":"91","author":"Moritz","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0058","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.neo.7900018","article-title":"Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen","volume":"1","author":"Gong","year":"1999","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0059","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/10430349950018968","article-title":"Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor","volume":"10","author":"McGuinness","year":"1999","journal-title":"Human gene therapy"},{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0060","doi-asserted-by":"crossref","first-page":"836","DOI":"10.4049\/jimmunol.157.2.836","article-title":"Single chain Ig\/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity","volume":"157","author":"Weijtens","year":"1996","journal-title":"Journal of immunology (Baltimore, Md.: 1950)"},{"issue":"12","key":"10.1016\/j.jcyt.2019.12.004_bib0061","first-page":"3928","article-title":"Bypassing immunization: optimized design of \"designer T cells\" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA","volume":"5","author":"Nolan","year":"1999","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"3","key":"10.1016\/j.jcyt.2019.12.004_bib0062","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nature medicine"},{"issue":"4","key":"10.1016\/j.jcyt.2019.12.004_bib0063","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2002-07-1989","article-title":"T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect","volume":"101","author":"Cooper","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2019.12.004_bib0064","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ymthe.2003.12.011","article-title":"Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes","volume":"9","author":"Wang","year":"2004","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"11","key":"10.1016\/j.jcyt.2019.12.004_bib0065","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.gt.3301467","article-title":"T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells","volume":"8","author":"Hombach","year":"2001","journal-title":"Gene therapy"},{"issue":"6","key":"10.1016\/j.jcyt.2019.12.004_bib0066","first-page":"1001","article-title":"Cytolysis of tumor cells expressing the Neu\/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes","volume":"2","author":"Altenschmidt","year":"1996","journal-title":"Clinical cancer research"},{"issue":"24","key":"10.1016\/j.jcyt.2019.12.004_bib0067","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1158\/0008-5472.CAN-04-0454","article-title":"Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells","volume":"64","author":"Kahlon","year":"2004","journal-title":"Cancer research"},{"issue":"9","key":"10.1016\/j.jcyt.2019.12.004_bib0068","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V84.9.2878.2878","article-title":"Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors","volume":"84","author":"Roberts","year":"1994","journal-title":"Blood"},{"issue":"132","key":"10.1016\/j.jcyt.2019.12.004_bib0069","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Science translational medicine"},{"issue":"12","key":"10.1016\/j.jcyt.2019.12.004_bib0070","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","article-title":"Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells","volume":"159","author":"Levine","year":"1997","journal-title":"Journal of immunology"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0071","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/scd.1.1998.7.437","article-title":"Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3\/CD28 costimulation","volume":"7","author":"Levine","year":"1998","journal-title":"Journal of hematotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0072","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm0102-47","article-title":"Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection","volume":"8","author":"Levine","year":"2002","journal-title":"Nature medicine"},{"issue":"3","key":"10.1016\/j.jcyt.2019.12.004_bib0073","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.clim.2004.03.004","article-title":"Immune reconstitution following autologous transfers of CD3\/CD28 stimulated CD4(+) T cells to HIV-infected persons","volume":"111","author":"Bernstein","year":"2004","journal-title":"Clinical immunology"},{"issue":"46","key":"10.1016\/j.jcyt.2019.12.004_bib0074","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.0608138103","article-title":"Gene transfer in humans using a conditionally replicating lentiviral vector","volume":"103","author":"Levine","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.jcyt.2019.12.004_bib0075","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"Journal of virology"},{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0076","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/jgm.2691","article-title":"Patient monitoring and follow-up in lentiviral clinical trials","volume":"15","author":"McGarrity","year":"2013","journal-title":"The journal of gene medicine"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0077","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ymthe.2017.09.008","article-title":"Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products","volume":"26","author":"Cornetta","year":"2018","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0078","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymthe.2017.10.012","article-title":"Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients","volume":"26","author":"Marcucci","year":"2018","journal-title":"Molecular therapy"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0079","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymthe.2017.12.003","article-title":"Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples","volume":"26","author":"Lyon","year":"2018","journal-title":"Molecular therapy"},{"issue":"6","key":"10.1016\/j.jcyt.2019.12.004_bib0080","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/mt.2013.67","article-title":"Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1","volume":"21","author":"Heinrich","year":"2013","journal-title":"Molecular therapy"},{"issue":"4","key":"10.1016\/j.jcyt.2019.12.004_bib0081","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.176.4.1125","article-title":"Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer","volume":"176","author":"Donahue","year":"1992","journal-title":"The Journal of experimental medicine"},{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0082","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Current opinion in immunology"},{"issue":"3950","key":"10.1016\/j.jcyt.2019.12.004_bib0083","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.169.3950.1042","article-title":"A theory of self-nonself discrimination","volume":"169","author":"Bretscher","year":"1970","journal-title":"Science (New York, N.Y.)"},{"issue":"7","key":"10.1016\/j.jcyt.2019.12.004_bib0084","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0092-8674(05)80059-5","article-title":"Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4","volume":"71","author":"Chen","year":"1992","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.jcyt.2019.12.004_bib0085","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1073\/pnas.90.12.5687","article-title":"Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules","volume":"90","author":"Baskar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0086","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nature biotechnology"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0087","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1182\/blood-2004-09-3737","article-title":"Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation","volume":"105","author":"Friedmann-Morvinski","year":"2005","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jcyt.2019.12.004_bib0088","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer research"},{"issue":"Suppl 2","key":"10.1016\/j.jcyt.2019.12.004_bib0089","first-page":"S42","article-title":"Targeting CD19 with genetically modified EBV-specific human T lymphocytes","volume":"81","author":"Roessig","year":"2002","journal-title":"Annals of hematology"},{"issue":"3","key":"10.1016\/j.jcyt.2019.12.004_bib0090","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.mt.6300404","article-title":"Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies","volume":"16","author":"Huang","year":"2008","journal-title":"Molecular therapy"},{"issue":"5-6","key":"10.1016\/j.jcyt.2019.12.004_bib0091","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leukemia & lymphoma"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0092","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/mt.sj.6300134","article-title":"Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules","volume":"15","author":"Suhoski","year":"2007","journal-title":"Molecular therapy"},{"issue":"7","key":"10.1016\/j.jcyt.2019.12.004_bib0093","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.4049\/jimmunol.179.7.4910","article-title":"4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy","volume":"179","author":"Zhang","year":"2007","journal-title":"Journal of immunology"},{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0094","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt0202-143","article-title":"Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB","volume":"20","author":"Maus","year":"2002","journal-title":"Nature biotechnology"},{"issue":"95","key":"10.1016\/j.jcyt.2019.12.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Science translational medicine"},{"issue":"14","key":"10.1016\/j.jcyt.2019.12.004_bib0096","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMp1711886","article-title":"Tragedy, Perseverance, and Chance\u2014The Story of CAR-T Therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0097","unstructured":"Penn Medicine News, University of Pennsylvania and Novartis Form Alliance to Expand Use of Personalized T Cell Therapy for Cancer Patients, 2012. https:\/\/www.pennmedicine.org\/news\/news-releases\/2012\/august\/university-of-pennsylvania-and. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0098","unstructured":"Gilead, Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products, 2012. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2012\/10\/kite-pharma-partners-with-the-national-cancer-institute-to-develop-novel-cellular-immunotherapy-clinical-products. (Accessed July 27, 2019)."},{"issue":"303","key":"10.1016\/j.jcyt.2019.12.004_bib0099","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Science translational medicine"},{"issue":"16","key":"10.1016\/j.jcyt.2019.12.004_bib0100","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0101","doi-asserted-by":"crossref","unstructured":"Maude SL, Pulsipher MA, Boyer MW, Grupp SA, Davies SM, Phillips CL, Verneris MR, August KJ, Schlis K, Driscoll TA, Mody R, Capitini CM, June CH, Levine BL, Wood PA, Yi L, Levine JE, Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed\/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis, 128(22) (2016) 2801-2801.","DOI":"10.1182\/blood.V128.22.2801.2801"},{"issue":"24","key":"10.1016\/j.jcyt.2019.12.004_bib0102","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clinical cancer research"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0103","first-page":"285","article-title":"Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells","volume":"8","author":"Stein","year":"2019","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0104","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"The New England journal of medicine"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0106","unstructured":"US Food and Drug Administration, Clinical Review\u2014KYMRIAH, 2017. https:\/\/www.fda.gov\/media\/107973\/download. (Accessed October 13, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0107","unstructured":"Penn Medicine News, University of Pennsylvania's Personalized Cellular Therapy for Leukemia Receives FDA's Breakthrough Therapy Designation, 2014. https:\/\/www.pennmedicine.org\/news\/news-releases\/2014\/july\/university-of-pennsylvanias-pe. (Accessed October 13, 2019.)"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0108","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research, Summary Minutes of the Oncologic Drugs Advisory Committee, July 12, 2017. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM573719.pdf. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0109","unstructured":"Gilead, Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL), 2015.https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2015\/12\/kite-pharma-receives-fda-breakthrough-therapy-designation-for-ktec19-for-the-treatment-of-refractory-aggressive-non-hodgkin-lymphoma-nhl. (Accessed October 13, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0110","unstructured":"U.S. Food and Drug Administration, FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma, 2017. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma. (Accessed July 27, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0111","unstructured":"Novartis, Find a Kymriah treatment center, 2019. https:\/\/www.us.kymriah.com\/treatment-center-locator\/. (Accessed September 28, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0112","unstructured":"Kite Pharma, Where can Yescarta be received?, 2019. https:\/\/www.yescarta.com\/treatment-centers. (Accessed September 28, 2019)."},{"issue":"11","key":"10.1016\/j.jcyt.2019.12.004_bib0113","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jcyt.2018.09.010","article-title":"Cell, tissue and gene products with marketing authorization in 2018 worldwide","volume":"20","author":"Cuende","year":"2018","journal-title":"Cytotherapy"},{"issue":"25","key":"10.1016\/j.jcyt.2019.12.004_bib0114","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0115","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0116","article-title":"Mechanisms of resistance to CAR T cell therapy, Nature reviews","author":"Shah","year":"2019","journal-title":"Clinical oncology"},{"issue":"21","key":"10.1016\/j.jcyt.2019.12.004_bib0117","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jcyt.2019.12.004_bib0118","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nature medicine"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0119","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.13562","article-title":"Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells","volume":"171","author":"Evans","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0120","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"American journal of hematology"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0121","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0122","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"The Journal of clinical investigation"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0123","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nature medicine"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0124","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Molecular therapy oncolytics"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nature medicine"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0126","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"The Journal of clinical investigation"},{"issue":"3","key":"10.1016\/j.jcyt.2019.12.004_bib0127","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.immuni.2017.03.010","article-title":"Successful and Maladaptive T Cell Aging","volume":"46","author":"Goronzy","year":"2017","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.jcyt.2019.12.004_bib0128","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"7655","key":"10.1016\/j.jcyt.2019.12.004_bib0129","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0130","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2019.12.004_bib0131","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1182\/blood-2018-99-115418","article-title":"Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate","volume":"132","author":"Gill","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0132","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2019.12.004_bib0133","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","article-title":"Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas","volume":"132","author":"Chong","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2019.12.004_bib0134","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0135","unstructured":"Yu JX, Hubbard-Lucey VM, Tang J, The global pipeline of cell therapies for cancer, 2019. https:\/\/www.nature.com\/articles\/d41573-019-00090-z. (Accessed July 31, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0136","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global Manufacturing of CAR T Cell Therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Molecular therapy. Methods & clinical development"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0137","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.2147\/DDDT.S175113","article-title":"Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system","volume":"12","author":"Zhang","year":"2018","journal-title":"Drug design, development and therapy"},{"issue":"6","key":"10.1016\/j.jcyt.2019.12.004_bib0138","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/hgtb.2016.120","article-title":"A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies","volume":"27","author":"Lu","year":"2016","journal-title":"Human gene therapy methods"},{"issue":"4","key":"10.1016\/j.jcyt.2019.12.004_bib0139","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ymthe.2017.03.007","article-title":"Showcasing Clinical Development and Production of Cellular Therapies","volume":"25","author":"Levine","year":"2017","journal-title":"Molecular therapy"},{"issue":"374","key":"10.1016\/j.jcyt.2019.12.004_bib0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Science translational medicine"},{"issue":"24","key":"10.1016\/j.jcyt.2019.12.004_bib0141","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jcyt.2019.12.004_bib0142","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clinical cancer research"},{"issue":"7643","key":"10.1016\/j.jcyt.2019.12.004_bib0143","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0144","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0145","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.jcyt.2019.12.004_bib0146","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14712598.2018.1484105","article-title":"Successful translation and future prospects of TALEN editing for leukemia patients","volume":"18","author":"Werner Sunderland","year":"2018","journal-title":"Expert opinion on biological therapy"},{"issue":"12","key":"10.1016\/j.jcyt.2019.12.004_bib0147","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.jcyt.2019.12.004_bib0148","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0149","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00262-012-1202-z","article-title":"CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer","volume":"61","author":"Chmielewski","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.jcyt.2019.12.004_bib0150","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.jcyt.2019.12.004_bib0151","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166891","article-title":"In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia","volume":"11","author":"Minagawa","year":"2016","journal-title":"PloS ONE"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0152","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized Depletion of Chimeric Antigen Receptor T-Cells in Murine Xenograft Models of Human Acute Myeloid Leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"6258","key":"10.1016\/j.jcyt.2019.12.004_bib0153","doi-asserted-by":"crossref","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0154","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer immunology research"},{"issue":"4","key":"10.1016\/j.jcyt.2019.12.004_bib0155","first-page":"E459","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0156","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","article-title":"Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia","volume":"25","author":"Arcangeli","year":"2017","journal-title":"Molecular therapy"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159477","article-title":"Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors","volume":"11","author":"Thokala","year":"2016","journal-title":"PloS one"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0158","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Molecular therapy"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0159","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nature biotechnology"},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer immunology research"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0161","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"Journal of clinical immunology"},{"issue":"10","key":"10.1016\/j.jcyt.2019.12.004_bib0162","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.jcyt.2019.12.004_bib0163","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/ijh-2016-0001","article-title":"Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant","volume":"5","author":"Maziarz","year":"2016","journal-title":"International journal of hematologic oncology"},{"issue":"5","key":"10.1016\/j.jcyt.2019.12.004_bib0164","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/10428194.2017.1375100","article-title":"Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma","volume":"59","author":"Maziarz","year":"2018","journal-title":"Leukemia & lymphoma"},{"issue":"6432","key":"10.1016\/j.jcyt.2019.12.004_bib0165","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.363.6432.1166","article-title":"Beyond survival","volume":"363","author":"Couzin-Frankel","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0166","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia","author":"Lin","year":"2018","journal-title":"Journal of clinical oncology"},{"issue":"7","key":"10.1016\/j.jcyt.2019.12.004_bib0167","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd.2018.74","article-title":"The global landscape of cancer cell therapy","volume":"17","author":"Tang","year":"2018","journal-title":"Nature reviews. Drug discovery"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0168","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","volume":"54","author":"Kansagra","year":"2019","journal-title":"Bone marrow transplantation"},{"key":"10.1016\/j.jcyt.2019.12.004_bib0169","unstructured":"Gilead, Gilead Sciences to Acquire Kite Pharma for $11.9 Billion, 2017. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2017\/8\/gilead-sciences-to-acquire-kite-pharma-for-119-billion. (Accessed October 13, 2019)."},{"key":"10.1016\/j.jcyt.2019.12.004_bib0170","unstructured":"The Economist Intelligence Unit, Bristol-Myers drives into CAR-T therapies, 2019. https:\/\/www.eiu.com\/industry\/article\/817665265\/bristol-myers-drives-into-car-t-therapies\/2019-02-18. (Accessed August 3, 2019)."},{"issue":"1","key":"10.1016\/j.jcyt.2019.12.004_bib0171","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy","volume":"134","author":"van Bruggen","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jcyt.2019.12.004_bib0172","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"8","key":"10.1016\/j.jcyt.2019.12.004_bib0173","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI insight"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324919309181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324919309181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:40:23Z","timestamp":1761442823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324919309181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":173,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1465324919309181"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.12.004","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}